why choose us

First received: February 02, 2023

Clinical Trial: Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy

Study Status: Completed

Recruit Status: RECRUITING

Condition: Breast Carcinoma

Study Type: INTERVENTIONAL


Official Title: AIPAC-003 (Active Immunotherapy and PAClitaxel): A Randomized, Double-blind, Placebo-controlled Phase 3 Trial Testing Eftilagimod Alpha (Soluble LAG-3) in HER2-neg/Low Metastatic Breast Cancer Pa

Brief Summary: The goal of this clinical trial is to compare the safety and efficacy of eftilagimod alpha (efti) in combination with paclitaxel standard of care chemotherapy in participants with metastatic breast cancer.The main questions it aims to answer are:What is the optimal biological dose (OBD) of efti in combination with weekly paclitaxel chemotherapy?Can efti combined with weekly paclitaxel chemotherapy prolong overall survival in participants with metastatic breast cancer if compared to weekly paclitaxel chemotherapy…

Read more